A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in untreatable advanced hepatocellular carcinoma patients

MCG0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•Age =>18 yrs
•- Histologically proven hepatocellular carcinoma
•- MDT-advised best supportive care for untreatable advanced HCC or patients unable to undergo or declining
•treatment for advanced HCC.
•- Minimal life expectancy of 3 months
•- Willing and able to attend follow-up examinations
•- Willing to stop driving until 2 weeks after the titration period, if applicable
•- Signed informed consent
•- Language: Dutch or English

•- Mental conditions rendering the subject incapable to understand the nature, scope and consequences of the
•- Use of medicinal cannabis for other purposes
•- Contra-indications for medicinal cannabis oil:
•o Patients who have experienced a myocardial infarction or clinically significant cardiac dysfunction within the
•last 12 months or have had a cardiac disorder that, in the opinion of the investigator would have put the
•participant at risk of a clinically significant arrhythmia or myocardial infarction.
•o Patients with known psychotic disorders
•o Female patients who are pregnant or lactating
•o Patients (men or women) intending to start a family
•o Hypersensitivity to cannabinoids or any of the excipients of the cannabis oil

发起方

MCG